文献速递胰腺与胆道疾病消化内镜

美国内镜逆行胰胆管造影术后胰腺炎预防的成本效益分析

A Cost-Effectiveness Analysis for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Prophylaxis in the United States.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-09-02

该研究通过决策树模型评估高危和平均风险患者中预防内镜逆行胰胆管造影术后胰腺炎(PEP)的策略。在高危患者中,与不预防相比所有策略均具成本效益,直肠吲哚美辛最具成本效益(31,589美元/QALY)。在平均风险患者中,直肠吲哚美辛和舌下硝酸盐具成本效益,直肠吲哚美辛最具成本效益(53,016美元/QALY)。

要点

  • 高危患者中所有PEP预防策略均具成本效益
  • 直肠吲哚美辛是高危和平均风险患者中最具成本效益的策略
  • 平均风险患者中积极乳酸林格氏液水化不具成本效益

核心结论

  • 直肠吲哚美辛是平均风险和高危患者中预防PEP最具成本效益的策略。

研究设计与样本

  • 研究构建两个独立决策树模型,分别评估高危和平均风险患者的PEP预防策略。
  • 高危患者比较直肠吲哚美辛、胰腺支架置入、支架联合吲哚美辛、舌下硝酸盐、积极乳酸林格氏液水化和不预防。
  • 平均风险患者比较直肠吲哚美辛、舌下硝酸盐、积极水化和不预防。
  • 支付意愿阈值为100,000美元/QALY。

主要发现

  • 高危患者中,与不预防相比所有策略在100,000美元/QALY阈值下均具成本效益。
  • 高危患者中直接比较,直肠吲哚美辛最具成本效益(31,589美元/QALY)。
  • 平均风险患者中,与不预防相比直肠吲哚美辛和舌下硝酸盐具成本效益。
  • 平均风险患者中直接比较,直肠吲哚美辛最具成本效益(53,016美元/QALY)。

关键数值与推荐

  • 支付意愿阈值为100,000美元/QALY。
  • 高危患者直肠吲哚美辛的增量成本效益比为31,589美元/QALY。
  • 平均风险患者直肠吲哚美辛的增量成本效益比为53,016美元/QALY。

临床怎么用

  • 对于接受ERCP的患者,可优先考虑直肠吲哚美辛预防PEP。
  • 高危患者可选择任一预防策略,但直肠吲哚美辛最具成本效益。
  • 平均风险患者应避免积极乳酸林格氏液水化作为预防策略。

局限性

  • 研究基于决策树模型,结果受模型假设和输入数据影响。
  • 需进一步研究提高PEP预防策略的利用率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most common adverse event after endoscopic retrograde cholangiopancreatography, and is responsible for substantial morbidity and health care expenditures of at least $200 million. Therapies for PEP prevention include pancreatic stent placement (PSP), rectal indomethacin, sublingual nitrates, and aggressive lactated Ringer's hydration. Our objective was to determine which PEP prophylactic strategies are cost effective. METHODS: We developed 2 separate decision trees to evaluate PEP prophylactic strategies. The first, in high-risk patients, compared rectal indomethacin, PSP, PSP with indomethacin, sublingual nitrates, aggressive hydration with lactated Ringer's, and no prophylaxis. The second, in average-risk patients, compared rectal indomethacin, sublingual nitrates, aggressive hydration, and no prophylaxis. We used incidence rates, transition probabilities, and costs from publications and public data sources. Outcome measures were reported as incremental cost-effectiveness ratios, with a willingness-to-pay (WTP) threshold of $100,000/quality-adjusted life years (QALYs). RESULTS: Compared with no prophylaxis, all strategies were cost effective at a WTP of $100,000 in preventing PEP in high-risk patients. When directly compared with each other, rectal indomethacin was the cost-effective strategy in high-risk patients ($31,589/QALYs). In average-risk patients, indomethacin and sublingual nitrates were cost effective at a WTP of $100,000/QALYs compared with no prophylaxis. When directly compared with each other, rectal indomethacin was the cost-effective strategy ($53,016/QALYs). CONCLUSIONS: Rectal indomethacin was the cost-effective strategy for preventing PEP in both average-risk and high-risk patients undergoing endoscopic retrograde cholangiopancreatography. All strategies were cost effective when compared with no prophylaxis in high-risk patients, whereas all strategies except for aggressive hydration with lactated Ringer's were cost effective in average-risk patients. Further studies are needed to improve the utilization of PEP prevention strategies.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Thiruvengadam NR, Saumoy M, Schneider Y, et al. A Cost-Effectiveness Analysis for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Prophylaxis in the United States. Clin Gastroenterol Hepatol. 2021. PMID: 34481952. doi:10.1016/j.cgh.2021.08.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。